Bay Harbor Wealth Management LLC Sells 155 Shares of Boston Scientific Corporation $BSX

Bay Harbor Wealth Management LLC decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 13.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 973 shares of the medical equipment provider’s stock after selling 155 shares during the quarter. Bay Harbor Wealth Management LLC’s holdings in Boston Scientific were worth $105,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in Boston Scientific by 15.4% during the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after purchasing an additional 3,932 shares during the period. Bank of New Hampshire boosted its stake in Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after purchasing an additional 16,699 shares during the period. MRA Advisory Group bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $273,000. NS Partners Ltd lifted its position in shares of Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after acquiring an additional 5,704 shares during the period. Finally, Neville Rodie & Shaw Inc. lifted its position in shares of Boston Scientific by 95.9% in the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider’s stock worth $4,883,000 after acquiring an additional 22,255 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on BSX shares. Royal Bank Of Canada reiterated an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a research report on Monday, September 29th. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research report on Saturday, September 27th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday. Finally, UBS Group raised their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $120.79.

Boston Scientific Trading Up 1.1%

Shares of BSX opened at $97.30 on Friday. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a 50 day simple moving average of $102.93 and a 200-day simple moving average of $102.06. The stock has a market cap of $144.17 billion, a PE ratio of 57.91, a PEG ratio of 2.34 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the prior year, the firm posted $0.62 EPS. Boston Scientific’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.